

**Anti-SLAMF7 / CS1 Reference Antibody (azintuxizumAb)  
Recombinant Antibody  
Catalog # APR10383****Specification**

---

**Anti-SLAMF7 / CS1 Reference Antibody (azintuxizumAb) - Product Information**

Application	FC, E, FTA
Primary Accession	<a href="#">O9NQ25</a>
Reactivity	Human, Cynomolgus
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	145.32 KDa

**Anti-SLAMF7 / CS1 Reference Antibody (azintuxizumAb) - Additional Information****Target/Specificity**  
SLAMF7 / CS1**Endotoxin**  
< 0.001EU/ µg,determined by LAL method.**Conjugation**  
Unconjugated**Expression system**  
CHO Cell**Format**  
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.**Anti-SLAMF7 / CS1 Reference Antibody (azintuxizumAb) - Protein Information****Name** SLAMF7**Synonyms** CS1**Function**

Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response. Activities are controlled by presence or absence of small cytoplasmic adapter proteins, SH2D1A/SAP and/or SH2D1B/EAT-2. Isoform 1 mediates NK cell activation through a SH2D1A-independent extracellular signal-regulated ERK-mediated pathway (PubMed:<a href="http://www.uniprot.org/citations/11698418" target="\_blank">11698418</a>). Positively regulates NK cell functions by a mechanism dependent on phosphorylated SH2D1B. Downstream signaling implicates PLCG1, PLCG2 and PI3K (PubMed:<a

<http://www.uniprot.org/citations/16339536> target="\_blank">16339536</a>). In addition to heterotypic NK cells-target cells interactions also homotypic interactions between NK cells may contribute to activation. However, in the absence of SH2D1B, inhibits NK cell function. Acts also inhibitory in T-cells (By similarity). May play a role in lymphocyte adhesion (PubMed:<a href="http://www.uniprot.org/citations/11802771" target="\_blank">11802771</a>). In LPS-activated monocytes negatively regulates production of pro-inflammatory cytokines (PubMed:<a href="http://www.uniprot.org/citations/23695528" target="\_blank">23695528</a>).

#### Cellular Location

Membrane; Single-pass type I membrane protein.

#### Tissue Location


Expressed in spleen, lymph node, peripheral blood leukocytes, bone marrow, small intestine, stomach, appendix, lung and trachea. Expression was detected in NK cells, activated B-cells, NK-cell line but not in promyelocytic, B-, or T-cell lines. Expressed in monocytes. Isoform 3 is expressed at much lower level than isoform 1

### Anti-SLAMF7 / CS1 Reference Antibody (azintuxizumAb) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

### Anti-SLAMF7 / CS1 Reference Antibody (azintuxizumAb) - Images



Anti-SLAMF7 / CS1 Reference Antibody (azintuxizumAb) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-SLAMF7 / CS1 Reference Antibody (azintuxizumAb) is more than 95% ,determined by SEC-HPLC.